Abstract (-)-Clausenamide is a drug candidate under Phase I clinical trial for treatment of Alzheimer's disease (AD). In order to elucidate the substituent related structure-activity relationship, six one-substituent modified (-)-clausenamide analogues were designed, and four of them, namely 3-0-methyl, 6-0-methyl, 3-des-hydroxyl and 6-des-hydroxyl analogues were prepared by selective 3- and 6- OH modification of (-)-clausenamide.
Received: 29 November 2010
Fund:This project was financially supported by Natural Science Foundation of China (No.30672530).
Xiao Ming Yu, E-mail address:email@example.com